LIMN

It appears you're asking about Liminatus Pharma, Inc. (NasdaqGM: LIMN). This is a preclinical stage biopharmaceutical company focused on developing innovative immune-modulating cancer therapies.

Here's a quick data-driven overview of LIMN:

• Company Focus: Liminatus Pharma specializes in developing novel cancer therapies, with their lead candidate, IBA101, being a humanized anti-CD47 monoclonal antibody aimed at treating advanced solid cancers, including non-small cell lung cancer. They have completed preclinical development and are preparing for an FDA Phase I clinical trial.
• Recent Market Activity: The company recently completed a business combination and began trading on The Nasdaq Stock Market LLC under the ticker symbol "LIMN" (and "LIMNW" for warrants) on May 1, 2025.
• Market Snapshot: As of August 6, 2025, Liminatus Pharma had a market capitalization of approximately $122.01 million. The share price on that date was $4.69, reflecting a decrease of 30.83% from the prior week.
• Institutional Ownership: Fintel data indicates that there are 6 institutional owners holding shares of LIMN, all of whom are long-only.
• Short Interest: The reported short interest for LIMN is 202,585 shares, with a short interest ratio of 0.66 Days to Cover. The borrow rate for shorting LIMN is notably high at 436.84%, which can be an indicator of high demand to short the stock or limited availability of shares.
• Financials: For the three months ended March 31, 2025, the company reported a net loss of $(255).

For a deeper dive into Liminatus Pharma's data, you can explore the following resources on Fintel:

• LIMN Stock Page: Provides real-time quotes, charts, and basic statistics: https://fintel.io/s/us/limn
• Institutional Ownership: See which institutions own LIMN and track changes in their positions: https://fintel.io/so/us/limn
• Short Interest Data: Monitor short interest, short volume, and borrow rates: https://fintel.io/ss/us/limn
• SEC Filings: Access all regulatory filings, including their recent 10-Q report for March 31, 2025: https://fintel.io/sf/us/limn

As always, it's crucial to conduct thorough due diligence and consider multiple factors before making any investment decisions.